Kyttaro Therapeutics was incorporated in the US in 2021 to commercialize technologies developed by the founders of Apceth Biopharma GmbH since 2007. The company is headquartered in New York, with research operations in Germany.

Kyttaro Therapeutics is a development-stage platform technology company with a unique patent portfolio in clinical applications of mesenchymal stem cells (MSCs) for treatment of diseases with a high, unmet clinical need.

Kyttaro’s expertise and intellectual property are based on 15 years of research and development in Germany and around the world in cutting-edge applications for MSC Alpha-1 Antitrypsin (MSC-AAT), MSC Cytokines (MSC-Cyt) and MSC-Klotho.

Kyttaro Therapeutics

Org chart

Teams

Offices